Trial reportCancer science2023
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02775435 (A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab), which is not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review.JAMA network open · 2025Pooled it
- First-line immunochemotherapy for advanced NSCLC in Asian patients: a meta-analysis of phase 3 RCTs.Frontiers in oncology · 2025Pooled it
- The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials.Frontiers in oncology · 2025Pooled it
- Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.Cancer science · 2025Trial
- Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.Cancer science · 2023Trial
- Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671.JTO clinical and research reports · 2026Article
- Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in stage IIIB-IV squamous non-small cell lung cancer: a systematic review and meta-analysis of phase 3 randomized controlled trials.Translational cancer research · 2026Article
- Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials.Translational cancer research · 2026Article
- Article
- Cemiplimab in Japanese patients with advanced non-small cell lung cancer.Japanese journal of clinical oncology · 2026Article
- Immune regulatory mechanisms in the tumor microenvironment and their applications in cancer therapy: from basic research to clinical translation.Frontiers in immunology · 2026Review
- Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach.Medical oncology (Northwood, London, England) · 2025Review
- Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902.JTO clinical and research reports · 2025Article
- KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.Investigational new drugs · 2024Article
- Monotherapy of PD-1 Inhibitor Camrelizumab Reverses Advanced Lung Squamous Cell Carcinoma with Low PD-1 Expression: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 20 institutions in 2 countries.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0002-3427-4558
Kentaro TanakaDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Fumio ImamuraDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Nobuyuki YamamotoThird Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
Makoto NishioDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4969-4165
Kyoichi OkishioDepartment of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka, Japan.
Tomonori HirashimaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hiroshi TanakaDepartment of Internal Medicine (Pulmonology), Niigata Cancer Center Hospital, Niigata, Japan.
Tatsuro FukuharaDepartment of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
Yasuharu NakaharaDepartment of Respiratory Medicine, National Hospital Organization Himeji Medical Center, Himeji, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0003-4123-3567
Nobuyuki KatakamiDepartment of Medical Oncology, Takarazuka City Hospital, Kobe, Japan.ORCID https://orcid.org/0000-0002-1851-5788
Morihito OkadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Hidehito HorinouchiDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9090-801X
Hibiki UdagawaDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0001-8822-2684
Kazuo KasaharaRespiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Miyako SatouchiDepartment of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.
Hideo SakaDepartment of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Takaaki TokitoDivision of Respirology, Neurology, and Rheumatology; Department of Internal Medicine, Kurume University, Kurume, Japan.
Yukio HosomiDepartment of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Keisuke AoeDepartment of Medical Oncology, Yamaguchi Ube Medical Center, Yamaguchi, Japan.
Kazuma KishiDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan.
Kadoaki OhashiDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.ORCID https://orcid.org/0000-0002-5180-3933
Takuma YokoyamaDepartment of Respiratory Medicine, Kyorin University Hospital, Tokyo, Japan.
Noriaki AdachiMSD K.K., Tokyo, Japan.
Kazuo NoguchiMSD K.K., Tokyo, Japan.
Paul SchwarzenbergerMerck & Co., Inc., Rahway, New Jersey, USA.
Terufumi KatoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
MSD K.K. (Japan) · JPHimeji Medical Center · JPHiroshima University · JPHyogo Prefectural Cancer Center · JPKanagawa Prefectural Hospital Organization · JPKanazawa University Hospital · JPKansai Medical University · JPKurume University · JPKyorin University Hospital · JPKyushu University · JPMerck & Co., Inc., Rahway, NJ, USA (United States) · USMiyagi Prefectural Hospital Organization · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JPNHO Kinki Chuo Chest Medical Center · JPNiigata Cancer Center Hospital · JPOkayama University Hospital · JPOsaka International Cancer Institute · JPOsaka Prefectural Medical Center · JPSendai Kousei Hospital · JP
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Abstract
The global phase III KEYNOTE-407 (NCT02775435) trial showed that pembrolizumab plus chemotherapy prolonged overall and progression-free survival (OS/PFS) versus placebo plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer (NSCLC). We present outcomes of patients from Japan enrolled in KEYNOTE-407. Patients were randomized 1:1 to receive pembrolizumab 200 mg or placebo with paclitaxel 200 mg/m
Indexed as
Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEast Asian PeopleHumansPaclitaxelAntibodies, Monoclonal, HumanizedPaclitaxelpembrolizumabcarcinomaclinical trialimmune checkpoint inhibitorimmunotherapyJapannon-small-cell lung cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT02775435ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.